• Cytokinetics President and CEO Robert I. Blum sold 7,500 shares on April 1, 2026 at $66.63.
• Direct holdings fell to 422,830 shares following transaction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytokinetics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001061983-26-000031), on April 01, 2026, and is solely responsible for the information contained therein.